Cancer
NY-ESO-1 157-165 mutant (HLA-A*02:01) 165V SLLMWITQV
€105.00*
Prices excl. VAT plus shipping
costs
Available, delivery time:
1-3 days
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity:
95% HPLC-MS
Caution:
For research use only. Not for use in humans.
Amount in mg
1
Product number: EP07862_1
Description
NY-ESO-1 157-165 (HLA-A*02:01) peptide SLLMWITQV for stimulation of T-cells. Single peptide SLLMWITQV for stimulation of human NY-ESO-1-specific CD8+ T-cells
SLLMWITQV is a linear peptidic epitope (epitope ID59283) studied as part of Other Homo sapiens (human) protein from Homo sapiens (human). This epitope has been studied for immune reactivity, tested in T cell assays, B cell assays and MHC ligand assaysNY-ESO-1 157-165 (HLA-A*02:01) peptide SLLMWITQV for stimulation of T-cells. Single peptide SLLMWITQV for stimulation of human NY-ESO-1-specific CD8+ T-cells
TechData
| Sequence: | SLLMWITQV |
| Gene: | CTAG1A |
| Delivery: | 1-3 days |
| C-Terminus: | OH |
| N-Terminus: | H |
| Amount: | 1 mg |
| Counterion: | TFA |
| Protein: | Cancer testis antigen, NY-ESO-1 |
| Species: | Human |
| Allele: | HLA-A*02:01 |
| Application: | Flow Cytometry |
| Indication: | Cancer |
| Purity: | 95% HPLC-MS |
Skip product gallery
More NY-ESO-1 peptides
NY-ESO-1 157-165 (HLA-A*02:01)
From
€105.00*
SLLMWITQC - The Essential Benchmark for Precision Immunotherapy
SLLMWITQC is not just another epitope—it is one of the most thoroughly characterized HLA-A*02:01 restricted sequences (epitope ID59278) in cancer immunology. Derived from both Cancer/testis antigen 1 (NY-ESO-1; UniProt: P78358) and the LAGE-1A isoform of Cancer/testis antigen 2 (UniProt: O75638-2), this peptide offers unique dual-targeting potential. It is the essential specialist tool for anyone developing or validating therapies aimed at these potent human tumor antigens.
Why this Peptide is Your Essential Specialist Tool
This peptide is the specific positive control to show if your anti-cancer weapon is functional.
Validate Your TCR-T Cells: Use SLLMWITQC to verify that your engineered T-cell receptors correctly recognize and react to their target.
Benchmark Vaccine Success: A critical reference to monitor if your vaccine has successfully primed an antigen-specific immune response.
Eliminate Assay Guesswork: As a high-affinity binder, it provides a reliable "on" signal, ensuring that your detection system (ELISpot, ICS, or Multimer staining) is working perfectly.
Proven Performance, IEDB-Validated
With over 500 validated T-cell assays and 85+ publications, SLLMWITQC is a trusted sequence for:
Cytokine Profiling: Reliable induction of IFN-ƴ, TNF-α, and IL-2.
Cytotoxicity Assays: The standard trigger for T-cell mediated tumor cell lysis.
In Vivo Benchmarking: Proven efficacy in reducing tumor burden in adoptive transfer models.
Your Research, Our Precision
At peptides&elephants, we support your NY-ESO-1 research with a modular toolkit of high-quality synthetic peptides. We provide SLLMWITQC as:
High-Quality Individual Peptide for precise kinetic and functional studies.
Part of a Targeted Sub-Pool with 5 key peptides for broader screening.
Part of our Complete Peptide Pool covering the entire 180 AA sequence.
Use the Button above to request a quote | Explore the NY-ESO-1 Insights Page
NY-ESO-1 158-166 (HLA-A*24:02)
From
€105.00*
NY-ESO-1 158-166 (HLA-A*24:02) peptide LLMWITQCF for stimulation of T-cells. Single peptide SLLMWITQV for stimulation of human NY-ESO-1-specific CD8+ T-cells. LLMWITQCF is a linear peptidic epitope studied as part of Other Homo sapiens (human) protein from Homo sapiens (human). This epitope has been studied for immune reactivity, tested in T cell assays, B cell assays and MHC ligand assays.
NY-ESO-1 86-94 (HLA-A*02:01)
From
€105.00*
NY-ESO-1 86–94 (RLLEFYLAM) is a well-characterized linear peptide epitope derived from the human cancer/testis antigen 1 (NY-ESO-1, UniProt: P78358). Restricted to HLA-A*02:01, this nonamer peptide has been extensively studied for its immunogenic potential in cancer immunology.
According to the Immune Epitope Database (IEDB epitope ID: 1075626), RLLEFYLAM has at least been:
Reported in 6 peer-reviewed publications
Tested in 7 T cell assays, demonstrating strong CD8⁺ T cell reactivity
Assessed in 1 B cell assay and 2 MHC ligand assays
Background on NY-ESO-1 and CTAs
NY-ESO-1 is one of the most immunogenic cancer/testis antigens (CTAs). CTAs are normally expressed only in germ cells of the testis but become aberrantly re-expressed in many cancers, including melanoma, lung, ovarian, and esophageal tumors. Because the testis is an immune-privileged site, the immune system does not develop tolerance to these antigens—making them highly attractive targets for cancer immunotherapy and immune monitoring.
These characteristics have positioned NY-ESO-1, and epitopes like RLLEFYLAM, at the center of research into cancer vaccines, adoptive T cell therapies, and diagnostic assays.
T cell epitope cluster
This peptide is part of an immunodominant cluster. Depending on your HLA-restriction of interest, you might also consider:
NY-ESO-1_LAGE-2 91-101 (YLAMPFATPME) – Optimized for HLA-A*24:02
NY-ESO-1 93-101 (AMPFATPME) – Optimized for HLA-B*07:02
NY-ESO-1 94-102 (MPFATPMEA) – Optimized for HLA-B*35:01 & HLA-B*51:01
peptides&elephants provides NY-ESO-1 86–94 with the highest quality standards, ensuring reliable results in immunological research and translational applications.
NY-ESO-1 93-101 (HLA-B*07:02)
From
€105.00*
The peptide epitope NY-ESO-1 93–101 (AMPFATPME) is derived from the human cancer/testis antigen 1 (NY-ESO-1) with the UniProt-ID P78358. This nonamer peptide (IEDB epitope ID: 2265540) is restricted to HLA-B*07:02 and has been investigated for its role in antigen-specific T cell responses in cancer immunology.
NY-ESO-1 and CTAs
NY-ESO-1 belongs to the family of cancer/testis antigens (CTAs), proteins typically restricted to germ cells of the testis but aberrantly expressed in many tumors, including melanoma, lung, ovarian, and esophageal cancers. Because of this unique expression profile and their strong immunogenicity, CTAs like NY-ESO-1 are widely recognized as prime targets for cancer immunotherapy, immune monitoring, and vaccine development.
NY-ESO-1 epitopes such as AMPFATPME contribute to dissecting CD8⁺ T cell responses and advancing the development of diagnostic assays and adoptive T cell therapies.
T cell epitope cluster
This peptide is part of an immunodominant epitope cluster. Depending on your HLA-restriction of interest, you might also consider:
NY-ESO-1 86-94 (RLLEFYLAM) – Optimized for HLA-A*02:01
NY-ESO-1_LAGE-2 91-101 (YLAMPFATPME) – Optimized for HLA-A*24:02
NY-ESO-1 94-102 (MPFATPMEA) – Optimized for HLA-B*35:01 & HLA-B*51:01
peptides&elephants supplies NY-ESO-1 93–101 with uncompromising quality, enabling reliable, reproducible, and translationally relevant results for immunological research.
NY-ESO-1 94-102 (HLA-B*35:01) (HLA-B*51:01)
From
€105.00*
NY-ESO-1-derived peptide of MPFATPMEA sequence covering 94-102 and HLA-B*35:01 HLA-B*51:01 molecule. The peptide NY-ESO-1 94-102 (HLA-B*35:01) (HLA-B*51:01) recognizes human CD8 T cells, and can be used in the analysis of individual antigen-specific T cells.
NY-ESO-1 Peptide Pool, human
€237.50*
Comprehensive Antigen Scan for Complete T-Cell Profiling
The NY-ESO-1 Peptide Pool from peptides&elephants is a high-performance tool designed for the thorough analysis of T-cell responses against Cancer/Testis Antigen 1 (NY-ESO-1).
Unlike focused sub-pools, this comprehensive pool consists of 43 overlapping peptides (15-mers with an 11-amino acid overlap) spanning the entire length of the NY-ESO-1 protein (UniProt ID: P78358). The peptide scan approach ensures that no potential epitope is missed, making it the ideal tool for screening both CD4+ and CD8+ T-cell responses regardless of the donor's HLA type.
The NY-ESO-1 Peptide Pool is optimized for T-cell assays such as ELISpot, ICS and Flow Cytometry.
Why Use a Full Antigen Scan?
The 15-mer overlapping strategy is the most robust method for immunological profiling:
Unbiased Discovery: Identifies all relevant epitopes across the entire protein sequence.
Dual Activation: The 15-amino acid length is ideal for presentation on both MHC Class I and Class II molecules, activating both CD8+ and CD4+ T-cells.
HLA-Independent: Suitable for use with any donor sample, as it covers all possible HLA-restricted motifs.
Applications & Scientific Validation
This peptide pool is a staple in clinical cancer research and immune monitoring. Its efficacy in detecting tumor-specific immune responses has been demonstrated in various high-impact studies.
Featured Research:
Our NY-ESO-1 pool was a key component in studying immune landscapes in gastrointestinal cancers. For a deep dive into the application of this pool in detecting tumor-associated antigens and HLA-I expression, read our detailed article:
👉 Esophagogastric adenocarcinoma: Tumor-associated antigens, immune responses and HLA-I ExpressionMap the full immune response to NY-ESO-1 with our validated NY-ESO-1 Peptide Pool.
NY-ESO-1_LAGE-2 91-101 (HLA-A*24:02)
From
€106.60*
HLA-A*24:02 Restricted Epitope for Cancer Immunotherapy
NY-ESO-1_LAGE-2 91-101 (YLAMPFATPME) is a well-characterized linear peptidic epitope (Epitope ID: 1075852) derived from the human Cancer/Testis Antigen 1 (NY-ESO-1; UniProt: P78358). This undecamer is a key target for studying immune reactivity in HLA-A*24:02 positive populations, a frequent allele in Asian and Caucasian cohorts.
Scientific Validation:
This epitope has been validated in peer-reviewed literature and immunological databases:
Immune Reactivity: Studied in multiple publications and confirmed in 4 independent T-cell assays.
Functional Response: Proven to trigger IFN-gamma release and specific cytotoxicity.
MHC Binding: Documented positive qualitative binding for HLA-A*24:02.
Applications:
Monitoring of antigen-specific CD8+ T-cell responses.
Validation of TCR-T cell therapies and cancer vaccine candidates.
Cytotoxicity assays (CTL assays) for oncology research.
NY-ESO-1_LAGE-2 91-101 is part of an immunodominant cluster. Depending on your HLA-restriction of interest, you might also consider:
NY-ESO-1 86-94 (RLLEFYLAM) – Optimized for HLA-A*02:01
NY-ESO-1 93-101 (AMPFATPME) – Optimized for HLA-B*07:02
NY-ESO-1 94-102 (MPFATPMEA) – Optimized for HLA-B*35:01 & HLA-B*51:01
NY-ESO1 Sub Peptide Pool (>95% HPLC)
€138.20*
The NY-ESO-1 Sub Peptide Pool from peptides&elephants is a specialized collection of 5 highly validated, overlapping peptides derived from the human Cancer/Testis Antigen 1 (NY-ESO-1; UniProt ID: P78358).
While full protein scans provide a broad overview, this Sub Pool focuses on key immunodominant regions, including the reference epitope SLLMWITQC. This high quality peptide pool is the ideal tool for precise T-cell monitoring, TCR-validation, and the development of targeted cancer vaccines.
Included Peptide Sequences
The NY-ESO-1 Sub Peptide Pool covers a diverse range of HLA restrictions, ensuring broad applicability across different donor profiles:
SLLMWITQC: NY-ESO-1 157-165 (HLA-A*02:01)SLLMWITQV: NY-ESO-1 157-165 mutant (HLA-A*02:01) 165VLLMWITQCF: NY-ESO-1 158-166 (HLA-A*24:02)TVSGNILTIR: NY-ESO-1 127-136 (HLA-A*68:01)MPFATPMEA: NY-ESO-1 94-102 (HLA-B*35:01) (HLA-B*51:01)
Key Applications
Antigen-Specific T-Cell Stimulation: Ideal for ELISpot, Intracellular Cytokine Staining (ICS), and flow cytometry assays.
TCR-T Cell Validation: A critical positive control for verifying the specificity and potency of engineered T-cell receptors.
Immune Monitoring: Reliable benchmarking of patient immune responses in clinical trials and vaccination studies.
Epitope Mapping: Focused screening of dominant NY-ESO-1 regions across multiple HLA alleles.